Uric acid in Parkinson's disease
Identifieur interne : 002051 ( Istex/Corpus ); précédent : 002050; suivant : 002052Uric acid in Parkinson's disease
Auteurs : Ilana Schlesinger ; Naomi SchlesingerSource :
- Movement Disorders [ 0885-3185 ] ; 2008-09-15.
English descriptors
- KwdEn :
Abstract
Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22139
Links to Exploration step
ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CBLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Uric acid in Parkinson's disease</title><author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name><affiliation><mods:affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel</mods:affiliation></affiliation></author><author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name><affiliation><mods:affiliation>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22139</idno><idno type="url">https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002051</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Uric acid in Parkinson's disease</title><author><name sortKey="Schlesinger, Ilana" sort="Schlesinger, Ilana" uniqKey="Schlesinger I" first="Ilana" last="Schlesinger">Ilana Schlesinger</name><affiliation><mods:affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel</mods:affiliation></affiliation></author><author><name sortKey="Schlesinger, Naomi" sort="Schlesinger, Naomi" uniqKey="Schlesinger N" first="Naomi" last="Schlesinger">Naomi Schlesinger</name><affiliation><mods:affiliation>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-09-15">2008-09-15</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1653">1653</biblScope><biblScope unit="page" to="1657">1657</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno><idno type="DOI">10.1002/mds.22139</idno><idno type="ArticleID">MDS22139</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>neuroprotection</term><term>urate</term><term>uric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Ilana Schlesinger MD</name><affiliations><json:string>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel</json:string></affiliations></json:item><json:item><name>Naomi Schlesinger MD</name><affiliations><json:string>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>uric acid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>urate</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>5.171</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>926</abstractCharCount><pdfWordCount>3287</pdfWordCount><pdfCharCount>20034</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>157</abstractWordCount></qualityIndicators><title>Uric acid in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>5</total><last>1657</last><first>1653</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Review</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.22139</json:string></doi><id>1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Uric acid in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Uric acid in Parkinson's disease</title><author><persName><forename type="first">Ilana</forename><surname>Schlesinger</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Head, Movement Disorders Clinic, Department of Neurology, Rambam Health Care Campus, Haifa, Israel 31096</p></note><affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel</affiliation></author><author><persName><forename type="first">Naomi</forename><surname>Schlesinger</surname><roleName type="degree">MD</roleName></persName><affiliation>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-09-15"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1653">1653</biblScope><biblScope unit="page" to="1657">1657</biblScope></imprint></monogr><idno type="istex">1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</idno><idno type="DOI">10.1002/mds.22139</idno><idno type="ArticleID">MDS22139</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>uric acid</term></item><item><term>urate</term></item><item><term>Parkinson's disease</term></item><item><term>neuroprotection</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Review</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2008-03-03">Received</change><change when="2008-04-27">Registration</change><change when="2008-09-15">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/1B52768F1AF1D4E52BE36D781E990E3059B4D3CB/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v23:12</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2008-09-15">15 September 2008</coverDate></publicationMeta><publicationMeta level="unit" type="reviewArticle" position="20" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22139</doi><idGroup><id type="unit" value="MDS22139"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Reviews</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2008-03-03"></event><event type="manuscriptRevised" date="2008-04-24"></event><event type="manuscriptAccepted" date="2008-04-27"></event><event type="publishedOnlineEarlyUnpaginated" date="2008-07-10"></event><event type="firstOnline" date="2008-07-10"></event><event type="publishedOnlineFinalForm" date="2008-09-25"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1653</numbering><numbering type="pageLast">1657</numbering></numberingGroup><correspondenceTo>Head, Movement Disorders Clinic, Department of Neurology, Rambam Health Care Campus, Haifa, Israel 31096</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22139.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="48"></count><count type="wordTotal" number="3314"></count></countGroup><titleGroup><title type="main" xml:lang="en">Uric acid in Parkinson's disease</title><title type="short" xml:lang="en">Uric Acid in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Ilana</givenNames><familyName>Schlesinger</familyName><degrees>MD</degrees></personName><contactDetails><email>i_schles@rambam.health.gov.il</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Naomi</givenNames><familyName>Schlesinger</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IL" type="organization"><unparsedAffiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">uric acid</keyword><keyword xml:id="kwd2">urate</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword><keyword xml:id="kwd4">neuroprotection</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Uric acid in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Uric Acid in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Uric acid in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Ilana</namePart><namePart type="family">Schlesinger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Head, Movement Disorders Clinic, Rambam Health Care Campus, Haifa, Israel</affiliation><description>Correspondence: Head, Movement Disorders Clinic, Department of Neurology, Rambam Health Care Campus, Haifa, Israel 31096</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Naomi</namePart><namePart type="family">Schlesinger</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Division of Rheumatology, University of Medicine and Dentistry of New Jersey/Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">reviewArticle</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-09-15</dateIssued><dateCaptured encoding="w3cdtf">2008-03-03</dateCaptured><dateValid encoding="w3cdtf">2008-04-27</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">48</extent><extent unit="words">3314</extent></physicalDescription><abstract lang="en">Recent studies have provided evidence that uric acid may play a role in the development and progression of Parkinson's disease (PD). Uric acid is a natural antioxidant that may reduce oxidative stress, a mechanism thought to play a role in the pathogenesis of PD. Higher levels of serum urate (SU) may have a neuroprotective effect. High SU levels reduced the risk of developing PD and correlated with slower PD progression. Among PD patients SU levels were lower as compared with controls. The manipulation of SU levels holds promise in the treatment of PD. It is possible that a high purine diet in patients with PD may slow progression of the disease. Milk and meat consumption as well as exercise modify the risk of developing PD possibly through their influence on SU levels. In this article, we review the association between PD and SU levels and its implication on the management of PD. © 2008 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>uric acid</topic><topic>urate</topic><topic>Parkinson's disease</topic><topic>neuroprotection</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Review</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1653</start><end>1657</end><total>5</total></extent></part></relatedItem><identifier type="istex">1B52768F1AF1D4E52BE36D781E990E3059B4D3CB</identifier><identifier type="DOI">10.1002/mds.22139</identifier><identifier type="ArticleID">MDS22139</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002051 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002051 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1B52768F1AF1D4E52BE36D781E990E3059B4D3CB
|texte= Uric acid in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |